Navigation Links
Alaven Pharmaceutical Introduces Kit for UC Patients
Date:6/9/2008

MARIETTA, Ga., June 9 /PRNewswire/ -- When patients with ulcerative colitis (UC) flare, their normal life can be completely disrupted. Bloody diarrhea, frantic urgency and abdominal pain make the bathroom the center of attention.

Alaven Pharmaceutical LLC, a specialty pharmaceutical company focused on developing and commercializing products to treat gastrointestinal conditions, today announced the introduction of a convenience Kit at the American Society of Colon and Rectal Surgeons' annual meeting in Boston. The Kit contains ROWASA(R) (mesalamine) Rectal Suspension Enema 4g/60mL, a treatment for flare symptoms associated with active mild to moderate left-sided UC, proctosigmoiditis, or ulcerative proctitis, and a personal cleansing wipe for added convenience for those inevitable restroom stops.*

"There is a continued need in the marketplace for convenient UC therapy for all patients living with the disease and facing the inevitability of flares," said Connie Swanson, VP, Sales and Marketing at Alaven. "Our hope is that by offering ROWASA in a convenience kit, patients will have access to a soothing topical treatment for more immediate flare relief and that they will be more comfortable with their medication-taking routine."

ROWASA is a prescription medication administered at bedtime for the relief of UC flare symptoms. Applied directly to the site of inflammation, ROWASA reduces rectal bleeding in as little as 3 days(1) and provides fast relief of diarrhea, abdominal pain, and other flare symptoms(2). The full course of treatment with ROWASA (3-6 weeks) is recommended for more complete flare relief(2).

Due to the unpredictable course of UC that is marked by periods of inactivity and then incidences of intermittent flares, patients are at an increased risk for poor adherence to medications. An estimated 34% of patients with left-sided UC have been shown to be non-compliant to prescribed medications(3). Research also shows that innovative ways, including providing convenient medications, may help to motivate patients to adhere(3).

The ROWASA convenience kit helps to improve the delivery and accessibility to reliable UC flare therapy while offering value-added convenience from a personal cleansing wipe that leaves UC patients clean and fresh.*

For additional information, visit http://www.ROWASA.com .

Important Safety Information

Contraindications: ROWASA is contraindicated for patients known to have hypersensitivity to the drug or any component of this medication.

Warning: ROWASA contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.

Precautions: Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. Caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine.

Adverse Reactions: ROWASA is usually well tolerated. Most adverse effects have been mild and transient. The most frequently reported adverse events include abdominal cramps, headache, gas, nausea, flu, fatigue, fever and rash.
For Full Prescribing Information - http://www.ROWASA.com .

*Wipe is optional and not a required part of treatment

1 Sutherland LR, et al. 5-aminosalicylic acid enema in the treatment of

distal ulcerative colitis, proctosigmoiditis, and proctitis.

Gastroenterology. 1987;92(6):1894-1898.

2 ROWASA Prescribing Information. Rev 05/08.

3 Kane SV, et al: The Challenge of Compliance and Persistence: Focus on

Ulcerative Colitis. J Manag Care Pharm. 2008;14(1)(suppl S-a):S2-S12.

Contact: Rose Raus

404-964-1834

rraus@dodgecommunications.com


'/>"/>
SOURCE Alaven Pharmaceutical LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones ... estate planning process, or where to even begin. “Now more than ever there are ... to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, founder of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is ... day to clean, plant trees and look forward to a better future. However, supporting ... doing something outdoors. Indoor air quality can be two to five times more polluted ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana Fiber ... bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit data ... consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access now ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology: